Fig. 1: Dis/agreement among MRD testing methods.

A Dis/agreement between next-generation sequencing (NGS) and other measurable residual disease (MRD) assays. B Dis/agreement between immunofixation (IFIX) and MRD assays. *Mass spectrometry (MS) identified a monoclonal protein of a different isotype from IFIX. LC-MS liquid chromatography mass spectrometry, MALDI-TOF-MS matrix‐assisted laser desorption ionization time‐of‐flight, MFC multiparameter flow cytometry, PET/CT positron emission tomography/computed tomography.